Clinical Trial Update: A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1/2 open-label, single-arm study evaluating nanobody-based CD5-CAR T cell therapy for relapsed/refractory T-cell malignancies is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Malignancies

Drugs mentioned

• CD5-CAR T cell therapy (Nanobody)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1, Phase 2 | Status: RECRUITING